semaglutide cardiovascular outcomes news today 2025 🔴Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants US FDA approves weight loss

(PubMed) Salinthone S, Schillace RV, Marracci GH, Bourdette DN, Carr DW

If weight loss is your athletes goal, its important to speak not just to their doctor, but also a registered dietitian, psychologist, and their coach in order to decide on the safest, healthiest path forward for your athlete

prescribers should verify current supply.) Tirzepatide (Mounjaro) a dual GIP/GLP-1 receptor agonist administered as a once-weekly subcutaneous injection, licensed for type 2 diabetes

Comprehensive Wellness: Beyond skincare, this complex supports overall health, enhancing your bodys natural detoxification process and bolstering your immune system with its potent antioxidant content.